Clinical Trial Update: Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating REGN6569 in combination with cemiplimab in adults with advanced solid tumors, including head and neck squamous cell carcinoma. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of Head and Neck

Drugs mentioned

• Cemiplimab (cemiplimab)
• REGN6569

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 1 | Status: TERMINATED